Citations

Clear

273 citation(s) found for "Simone, N De".

Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Abstract B022: Prediction of radiotherapy-Induced esophagitis in non-small cell lung cancer using a 3D vision foundation model
Choi, Chloe Min Seo, Jiang, Jue , Chang, John, Vargas, Carlos , Urbanic, James J., McDonald, Mark, Gray, James R. , Thor, Maria, Veeraraghavan, Harini, Mankuzhy, Nikhil P. , Zeng, Jing , Choi, Isabella, Deasy, Joseph O. , Simone, Charles B. , Veeraraghavan, Harini

Mayo Clinic

Clinical Cancer Research | July 10, 2025 | Volume: 31 | Issue: 13_Supplement | Pages: B022-B022

10.1158/1557-3265.aimachine-b022 Get It

Abstract Introduction: Radiotherapy (RT)-induced acute esophagitis (AE) is a common side effect in lung cancer patients receiving RT, which can significantly impact their quality of life. This highlights the need for a predictive model that can estimate AE risk in advance using pretreatment imaging data. However, collecting sufficient data for model development is often resource-intensive and costly. Additionally, acquiring a homogeneous training dataset (e.g., from a single center or modality) is not always feasible. This study aimed to develop an automated artificial intelligence-based 3D vision foundation model (VFM) combining standard-of-care planning computed tomography (pCT) and planned radiation dose maps to predict grade II or higher AE. Materials and methods: This study included 246 patients with non-small cell lung cancer who underwent either image-guided radiation treatment (IMRT) or proton-beam radiation therapy. The endpoint was grade two or higher AE (33% positive and 67% negative). The IMRT group consisted of 182 patients from a single center, whereas the proton therapy group included 64 patients from the Proton Collaborative Group trial from 11 different institutions. For each patient, pCT, dose maps, and radiotherapy segmentations were available. The VFM was created using a transformer pretrained using a large number of unlabeled volumetric 3D CTs from patients with varied diseases through a self-supervised learning approach, which extracts useful features directly from images. Next, the pretrained encoder was combined with fully connected classification layers and fine-tuned using stratified 5-fold cross-validation with 20 patients set aside for testing. We developed two models: a CT only and CT + dose model. Model performance was assessed using the area under the curve (AUC), specificity, and sensitivity. Results: In cross-validation, adding dose information to CT (CT+Dose) improved model performance, increasing AUC from 0.72 ± 0.08 to 0.76 ± 0.10 and specificity from 0.82 ± 0.09 to 0.87 ± 0.04, while sensitivity remained the same. On the independent test set, CT+Dose showed a marked improvement over CT only (AUC: 0.82 vs. 0.59; sensitivity: 0.57 vs. 0.14), with a slight decrease in specificity (0.77 vs. 1.00). Conclusion: A VFM model combining CT and radiation dose showed the capability to predict AE more accurately with higher specificity. Further studies on larger cohorts of testing patients are planned to assess model generalization. Citation Format: Chloe Min Seo Choi, Jue Jiang, Nikhil Mankuzhy, John Chang, Jing Zeng, Carlos Vargas, James Urbanic, Isabella Choi, Mark Mcdonald, James Gray, Joseph Deasy, Maria Thor, Charles Simone, Harini Veeraraghavan. Prediction of radiotherapy-Induced esophagitis in non-small cell lung cancer using a 3D vision foundation model [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning; 2025 Jul 10-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(13_Suppl):Abstract nr B022.
TDP-43 pathology induces CD8 + T cell activation through cryptic epitope recognition
Chizari, Shahab , Kong, Steven Lingyang, Saigal, Vidur J., Turchetti, Valentina, Chen, Bingxian, Devine, Connor C., Zampedri, Luca, Skorupinska, Iwona, Minicuci, Giacomo Maria, Paron, Francesca, Tonin, Paola , Marchetto, Giulia, Li, Ziyi , Colón-Mercado, Jennifer M., Barattucci, Simone, Soltic, Darija, Dattilo, Dario, Gatt, Ariana, Hembrador, Jada M., Capasso, Guido, Frezzato, Federica, Trentin, Livio, Lin, Elisabeth, Lopes, Raquel, Routledge, Nathan, Qi, Yue A., Hanna, Michael G., Ward, Michael, Petrucelli, Leonard , Buratti, Emanuele , Machado, Pedro , Fratta, Pietro, Jiang, Ning , Hanna, Michael G. , Ward, Michael E. , Fratta, Pietro , Fratta, Pietro , Kong, Steven , Ward, Michael E , Romano, Maurizio , Machado, Pedro M , Fratta, Pietro , Fratta, Pietro , Zanovello, Matteo , Brown, Anna‐Leigh , Chen, Bingxian, Devine, Connor C., Zampedri, Luca, Skorupinska, Iwona, Minicuci, Giacomo Maria, Paron, Francesca, Marchetto, Giulia, Li, Ziyi, Colón-Mercado, Jennifer M., Barattucci, Simone, Soltic, Darija, Dattilo, Dario, Gatt, Ariana P. , Hembrador, Jada M., Capasso, Guido, Frezzato, Federica, Trentin, Livio, Lin, Elisabeth, Lopes, Raquel, Routledge, Nathan, Qi, Yue A., Hanna, Michael G., Ward, Michael, Vattemi, Gaetano Nicola Alfio , Malaspina, Andrea , Merve, Ashirwad , Sorarú, Gianni , Jiang, Ning

Mayo Clinic

No container title available | June 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.22.660773 | PMID 40667053 Get It

Abstract Aggregation and nuclear depletion of the RNA binding protein TDP-43 are the crucial pathological features of amyotrophic lateral sclerosis (ALS) and inclusion body myositis (IBM), two degenerative diseases of the CNS and muscle. The loss of TDP-43 nuclear function results in the aberrant inclusion of cryptic exons in mRNA transcripts, leading to the expression of de novo proteins. Clonally expanded and highly differentiated CD8 + T cells have been observed in individuals with TDP-43 proteinopathies and therapeutics modulating the T cell response have recently been found to extend survival. However, the target antigens mediating T cell activation have remained elusive. Here, we investigate whether the de novo proteins induced by aberrant cryptic splicing due to TDP-43 nuclear loss can act as neo-antigens. We detect the HDGFL2 cryptic peptide and multiple other TDP-43 cryptic exons in IBM skeletal muscle, where their presence correlates with enrichment of T cells and class I antigen presentation pathways. Furthermore, we identify epitopes deriving from HDGFL2 and IGLON5 cryptic peptides which are recognized by clonally expanded and functionally differentiated populations of CD8 + T cells in ALS and IBM Patients. Finally, we demonstrate that T cells engineered to express the identified TCRs can bind and activate in response to the cryptic peptide derived epitopes (cryptic epitopes) and are able to kill TDP-43 deficient astrocytes. This work identifies for the first time specific T cell antigens in ALS and IBM, directly linking adaptive immune response to TDP-43 pathology.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Use of Esophageal Stents in Patients With Esophageal Cancer
Russo, Suzanne , Anker, Christopher J. , Codipilly, Don C. , Abood, Gerard, Akselrod, Dmitriy , Hallemeier, Christopher L. , Kennedy, Timothy J., Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Jin, Zhaohui , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Small, William , Tchelebi, Leila T. , Simone, Charles B.

Mayo Clinic

American Journal of Clinical Oncology | June 25, 2025 | Volume: 48 | Issue: 12 | Pages: 579-599

10.1097/coc.0000000000001222 | PMID 40557604 Get It

Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence. Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents. Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment. Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence.
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, Constance , Martinez‐Yriarte, Jose, Zecca, Chiara , Körtvelyessy, Péter , Tumani, Hayrettin , Quadrio, Isabelle , Hart, Melanie , Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Galimberti, Daniela , Gezen‐Ak, Duygu , Gouju, Julien , Flórez, Silvia de las Heras , Sanchez, Juanjo Hernandez, Herwerth, Marina , Imperiale, Daniele , Kaczorowski, Flora, Keshavan, Ashvini , Leithner, Christoph , Blanc, M, Rodríguez, Jose Enrique Martínez, Musso, Giulia , Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates J., Tzartos, John , Unterwalder, Nadine, Lehmann, Sylvain , Keshavan, Ashvini , Galimberti, Daniela , Herwerth, Marina , Ladang, Aurélie , Logroscino, Giancarlo , Tumani, Hayrettin , Parchi, Piero , Alcolea, Daniel , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Santos, Gustavo Alves Andrade dos , Borelli, Wyllians Vendramini , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Gordon, Brian A. , Sanchez, Juanjo Hernandez, Kasuga, Kensaku , Khalil, Michael , Kühle, Jens , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Mroczko, Barbara , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Halbgebauer, Steffen , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 23, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70343 | PMID 40551293 Get It

Abstract INTRODUCTION Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post‐analytical methods used for NfL measurement in routine clinical practice across different contexts. METHODS We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements. RESULTS Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%). DISCUSSION Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice. Highlights Unique international overview of current analytical and post‐analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.
THE 2024 FORMAL EU-US MENISCUS REHABILITATION CONSENSUS: AN ESSKA-AOSSM-AASPT INITIATIVE – PART II: Prevention, Non-Operative Treatment, and Return to Sport
Benjamin, C. , Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Becker, Roland , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J. , Klugarová, Jitka , Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Rambaud, Alexandre , Robinson, James , Schmitt, Laura C. , Giordano, Airelle O., Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Prill, Robert , Wong, Stephanie E. , Villa, Francesco Della, Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Pujol, Nicolas

Mayo Clinic

International Journal of Sports Physical Therapy | June 12, 2025 | Volume: 20 | Issue: 7 | Pages: No page available

10.26603/001c.140661 Get It

Purpose Part-two of this consensus aimed to provide recommendations for the prevention of meniscus injuries, non-operative treatment of acute tears and degenerative lesions, return to sports, and patient-reported outcome measures. Methods This consensus followed the European Society of Knee Surgery, Sports Traumatology and Arthroscopy (ESSKA) formal consensus methodology. For this combined ESSKA- American Orthopedic Society for Sports Medicine (AOSSM) - American Academy of Sports Physical Therapy (AASPT) initiative, 67 experts from 14 countries, including orthopedic surgeons and physiotherapists, were involved. The 26 Steering Group members established guiding questions, screened the existing evidence, and proposed statements, and provided Grades of recommendations. The 41 Rating Group members assessed the statements according to a Likert scale (1-9). Final documents were assessed by an international peer review group for geographical adaptability. Results Low to moderate scientific level of evidence was available, so that grades of recommendations were low (three Grade A ratings, four Grade B, three Grade C and 13 Grade D), underlining the relevance of this consensus. One strong and 17 relative agreements with overall median of 8 (8-9) and a mean of 7.92 +/- 0.37 were achieved for 23 statements on 18 questions. Prevention of meniscus injuries is possible with general knee injury reduction programs and through avoidance of certain activities. Non-Operative treatment including physical therapy is the first line approach for degenerative meniscus lesions and may be an option for some acute tears. Return to sports after meniscus tear surgery should be both criterion-based and time-based. Patient reported outcomes in combination with performance-based measures are recommended to evaluate the rehabilitation process. Conclusion This international EU-US consensus established recommendations for prevention strategies, describes rehabilitation of non-operated patients and of patients after partial meniscectomy, meniscus repair and meniscus reconstruction, and establishes return to sport criteria. These updated and structured recommendations may be applied by surgeons and physiotherapists. Level of Evidence I, Formal Consensus.
The Formal EU-US Meniscus Rehabilitation 2024 Consensus: An ESSKA-AOSSM-AASPT Initiative Part II—Prevention, Nonoperative Treatment and Return to Sport
Benjamin, C. , Beaufils, Philippe , Monllau, Joan Carles , Arhos, Elanna K. , Becker, Roland , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J. , Klugarová, Jitka , Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Rambaud, Alexandre , Schmitt, Laura C. , Giordano, Airelle O., Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Prill, Robert , Wong, Stephanie E. , Villa, Francesco Della, Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Pujol, Nicolas

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 12, 2025 | Volume: 13 | Issue: 6 | Pages: No page available

10.1177/23259671251349553 | PMID 40519541 Get It

Purpose: Part II of this consensus aimed to provide recommendations for the prevention of meniscus injuries, nonoperative treatment of acute tears and degenerative lesions, return to sports and patient-reported outcome measures. Methods: This consensus followed the European Society of Knee Surgery, Sports Traumatology and Arthroscopy (ESSKA) formal consensus methodology. For this combined ESSKA—American Orthopedic Society for Sports Medicine (AOSSM)—American Academy of Sports Physical Therapy (AASPT) initiative, 67 experts from 14 countries, including orthopedic surgeons and physiotherapists, were involved. The 26 Steering Group members established guiding questions, screened the existing evidence, and proposed statements, and provided Grades of recommendations. The 41 Rating Group members assessed the statements according to a Likert scale (1–9). Final documents were assessed by an international peer review group for geographical adaptability. Results: Low to moderate scientific level of evidence was available, so that grades of recommendations were low (3 Grade A ratings, 4 Grade B, 3 Grade C and 13 Grade D), underlining the relevance of this consensus. One strong and 17 relative agreements with overall median of 8 (8–9) and a mean of 7.92 ± 0.37 were achieved for 23 statements on 18 questions. Prevention of meniscus injuries is possible with general knee injury reduction programs and through avoidance of certain activities. Non-operative treatment including physical therapy is the first line approach for degenerative meniscus lesions and may be an option for some acute tears. Return to sports after meniscus tear surgery should be both criterion-based and timebased. Patient reported outcomes in combination with performance-based measures are recommended to evaluate the rehabilitation process. Conclusion: This international EU–US consensus established recommendations for prevention strategies, describes rehabilitation of nonoperated patients and of patients after partial meniscectomy, meniscus repair and meniscus reconstruction, and establishes return to sport criteria. These updated and structured recommendations may be applied by surgeons and physiotherapists. Level of Evidence: Level I, consensus.
The formal EU‐US Meniscus Rehabilitation 2024 Consensus: An ESSKA‐AOSSM‐AASPT initiative. Part II—Prevention, non‐operative treatment and return to sport
Prill, Robert , Benjamin, C. , Beaufils, Philippe , Monllau, Joan Carles , Arhos, Elanna K. , Becker, Roland , Villa, Francesco Della , Goodloe, J. Brett , Irrgang, James J. , Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Rambaud, Alexandre , Schmitt, Laura C. , Giordano, Airelle O., Ma, C Benjamin , Arhos, Elanna K , Becker, Roland , Villa, Francesco Della , Irrgang, James J , Klosterman, Emma L , Królikowska, Aleksandra , Krych, Aaron J , LaPrade, Robert F , van Melick, Nicky , Monson, Jill K , Paterno, Mark V , Piontek, Tomasz , Perelli, Simone , Rambaud, Alexandre , Hamrin Senorski, Eric , Tagliero, Adam , Pujol, Nicolas , Wong, Stephanie E. , Klugarová, Jitka , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Pujol, Nicolas

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | June 12, 2025 | Volume: 33 | Issue: 8 | Pages: 3014-3024

10.1002/ksa.12689 | PMID 40501314 Get It

AbstractPurposePart two of this consensus aimed to provide recommendations for the prevention of meniscus injuries, non‐operative treatment of acute tears and degenerative lesions, return to sports and patient‐reported outcome measures.MethodsThis consensus followed the European Society of Knee Surgery, Sports Traumatology and Arthroscopy (ESSKA) formal consensus methodology. For this combined ESSKA—American Orthopedic Society for Sports Medicine (AOSSM)—American Academy of Sports Physical Therapy (AASPT) initiative, 67 experts from 14 countries, including orthopedic surgeons and physiotherapists, were involved. The 26 Steering Group members established guiding questions, screened the existing evidence, and proposed statements, and provided Grades of recommendations. The 41 Rating Group members assessed the statements according to a Likert scale (1–9). Final documents were assessed by an international peer review group for geographical adaptability.ResultsLow to moderate scientific level of evidence was available, so that grades of recommendations were low (three Grade A ratings, four Grade B, three Grade C and 13 Grade D), underlining the relevance of this consensus. One strong and 17 relative agreements with overall median of 8 (8–9) and a mean of 7.92 ± 0.37 were achieved for 23 statements on 18 questions. Prevention of meniscus injuries is possible with general knee injury reduction programmes and through avoidance of certain activities. Non‐operative treatment including physical therapy is the first line approach for degenerative meniscus lesions and may be an option for some acute tears. Return to sports after meniscus tear surgery should be both criterion‐based and time‐based. Patient reported outcomes in combination with performance‐based measures are recommended to evaluate the rehabilitation process.ConclusionThis international EU–US consensus established recommendations for prevention strategies, describes rehabilitation of non‐operated patients and of patients after partial meniscectomy, meniscus repair and meniscus reconstruction, and establishes return to sport criteria. These updated and structured recommendations may be applied by surgeons and physiotherapists.Level of EvidenceLevel I, consensus.
Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC;
Kitchens, Caleah Simone, Dasari, Arvind , Hong, Theodore S. , Philip, Philip Agop, Baghdadi, Tareq Al, Bercz, Aron , George, Manju, Shergill, Ardaman , Hall, William A. , Kitchens, Caleah Simone, Shi, Qian , García‐Aguilar, Julio , Sanoff, Hanna K. , George, Thomas J. , Yothers, Greg , Alese, Olatunji B. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Horvat, Natally , Romesser, Paul B. , Smith, J. Joshua

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps3650 Get It

TPS3650 Background: A total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to neoadjuvant chemoradiation (CRT) alone in those with locally advanced rectal cancer. Recent data indicate that optimal sequencing of TNT involves consolidation (rather than induction) chemotherapy to improve complete response rates. The use of FOLFIRINOX has shown to improve response and outcomes compared to CRT and surgery alone. Data have also shown that patients with clinical complete response (cCR) after TNT may be managed with a watch and wait approach (WW) instead of preemptive total mesorectal resection (TME). However, the optimal consolidation chemotherapy regimen to improve cCR rates has not been established, and a randomized clinical trial has not robustly evaluated cCR as a primary endpoint. We designed this NCI-sponsored study of chemotherapy intensification to address this and to increase cCR rates, provide opportunity for organ preservation, and survival outcomes. Methods: In this multigroup randomized, seamless phase II/III trial (1:1), up to 760 patients with LARC, T4N0, any T with node positive disease (any T, N+) or T3N0 requiring abdominoperineal resection or coloanal anastomosis and distal margin within 12 cm of anal verge will be enrolled. Stratification factors include tumor stage (T4 vs T1-3), nodal stage (N+ vs N0) and distance from anal verge (0–4; 4–8; 8–12 cm). Patients will be randomized to receive neoadjuvant long-course chemoradiation (LCRT) followed by consolidation doublet (mFOLFOX6 or CAPOX (control arm)) or triplet chemotherapy (FOLFIRINOX (experimental arm)) for 3–4 months. LCRT in both arms involve 4500 cGy in 25 fractions over 5 weeks +900 cGy boost in 5 fractions with a fluoropyrimidine. Patients will undergo assessment 8–12 (±4) weeks post-TNT completion. The primary endpoint for the phase II portion will compare cCR between treatment arms. A total number of 312 patients (156 per arm) will provide statistical power of 90.5% to detect a 17% increase in cCR rate, at a one-sided alpha = 0.048. The primary endpoint for the phase III portion will compare disease-free survival (DFS) between arms. A total of 285 DFS events will provide 85% power to detect an effect size of hazard ratio 0.70 at a one-sided alpha of 0.025, requiring enrollment of 760 patients (380 per arm). Secondary objectives include overall survival, organ preservation time, time to distant metastasis, and adverse event rates. This study has accrued 587 patients as of January 2025, and is investigating exploratory correlatives (e.g., ctDNA). Support: U10CA180821, U10CA180882, U24 CA196171. https://acknowledgments.alliancefound.org. Clinicaltrials.gov ID: NCT05610163. Clinical trial information: NCT05610163 .
Comparative effectiveness of delivering early palliative care via video versus in-person on end-of-life outcomes in patients with advanced lung cancer.
Bauman, Jessica R. , El‐Jawahri, Areej , Rinaldi, Simone , Jackson, Vicki A. , Gallagher-Medeiros, Emily R., Rabideau, Dustin J. , Strand, Jacob J. , Zachariah, Finly , Shoemaker, Laura, Spoozak, Lori , Grey, Carl, Curseen, Kimberly , Szmuilowicz, Eytan , Rhodes, Ramona L. , Cullinan, Amelia , Horick, Nora , Bakitas, Marie , Jewett, Brianna, Temel, Jennifer S. , Greer, Joseph Andrew

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 1649-1649

10.1200/jco.2025.43.16_suppl.1649 Get It

1649 Background: Findings from our prior large-scale comparative effectiveness trial showed the equivalent effect of delivering early palliative care via video versus in-person on quality of life among patients with advanced non-small cell lung cancer (NSCLC). We now report on whether the two care delivery modalities were equivalent with respect to patient-reported communication with clinicians about their end-of-life (EOL) care preferences and hospice utilization. Methods: Between 6/14/2018 and 5/4/2023, we enrolled 1250 patients with newly diagnosed advanced NSCLC in a randomized trial of early palliative care across 22 US cancer centers. Patients were randomly assigned to meet with a palliative care clinician every 4 weeks from enrollment through the course of the disease, either via video or in the outpatient clinic. Participants completed self-report surveys at baseline and weeks 12, 24, 36, and 48, including an item asking if they had discussed with their clinicians the care they would want to receive if dying (yes/no); patients’ final assessments prior to death or last follow up were analyzed. We reviewed patients’ health records to collect data on hospice referral and length of stay. To test the equivalence in these outcomes, we used a binomial generalized linear model with the identity link function (pre-specified equivalence margin of ±8% for patient-reported communication about EOL care) and linear regression (pre-specified equivalence margin of ±6 days for mean length of stay in hospice). P-values were adjusted for multiplicity using a Bonferroni correction. Results: Of the 1250 enrolled participants, 888 (71.0%) completed at least one survey post baseline regarding whether they communicated with clinicians about EOL care preferences. Among those, 29.1% of the video group and 26.0% of the in-person group reported “yes,” indicating that they recalled such EOL care discussions (difference = 3.1%, 95% CI: -1.8%, 8.1%; p = 0.26 for equivalence). During the course of the trial, 733/1250 (58.6%) patients died, of whom 537/733 (73.3%) were referred to hospice. Mean lengths of hospice stay were 25.3 days for the video group versus 25.1 days for the in-person group (difference = 0.2, 95% CI: -7.0, 7.4; p = 0.46 for equivalence). When excluding outlying patients receiving hospice services > 180 days (n = 13), the mean lengths of hospice stay were 19.1 (video group) versus 19.7 (in-person group) days (difference = -0.6, 95% CI: -4.6, 3.3; p = 0.06 for equivalence). Conclusions: Although thresholds were not met to confirm equivalence statistically, the two modalities for delivering early palliative care demonstrate very similar outcomes with respect to patient-clinician communication about EOL care and hospice utilization. These findings provide further evidence of the utility of video visits for providing high quality palliative and EOL care. Clinical trial information: ClinicalTrials.gov Identifier ( NCT03375489 ) .